Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalence of Serum-Free vs Roller-Bottle Darbepoetin Alfa in CKD Anemia
NCT00121602Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2005
- Primary completion
- Oct 2005
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, randomised, double-blind trial of darbepoetin alfa in anemia (2 arms), sponsored by Amgen. Primary endpoints: Change in Hemoglobin level between screening/baseline and evaluation period at 30 weeks and Ratio of weekly dosing requirements between baseline and evaluation period at 28 weeks. Started Mar 2005; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00121602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121602.